Pharma-Bio Serv, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.5M
- Price
- $0.4161
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.15%
- Volume
- 1.0K
About
Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the pharmaceutical, chemical, biotechnology, medical device, cosmetic, and food industries, as well as related product companies. Its operational reach extends across Puerto Rico, the United States, Europe, and Brazil. The firm's technical advisory offerings encompass vital areas such as regulatory adherence, system validation, technology migration, engineering solutions, comprehensive project management, and ongoing process support. Established in 1993, Pharma-Bio Serv maintains its corporate headquarters in Dorado, Puerto Rico.
Quick stats
Shares outstanding22.9M
Computed float8.0M
Float / shares35.1%
Key info
SectorIndustrials
IndustrySpecialty Business Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001304161
Websitehttps://www.pbsvinc.com
AI Summary
AI-generated1/4
minorbullishearnings
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026
Pharma-Bio Serv reported Q3 revenue of approximately $2.3 million, up roughly $0.4 million versus the same period last year, with nine-month revenue of about $7.3 million, up approximately $0.5 million year over year.
The company posted a narrow Q3 net loss of $14 thousand, an improvement of about $190 thousand from the prior year, while nine-month net income reached approximately $252 thousand, up roughly $352 thousand year over year.
CEO Victor Sanchez attributed the improved performance to client relationships, sharper focus on markets where the firm's regulatory and compliance expertise creates competitive advantage, and continued operating efficiencies, and said he expects momentum to carry through the final quarter of the fiscal year.
Red flags
- Q3 posted a small net loss ($14 thousand) despite YoY revenue growth — profitability remains thin
- OTCQB-listed micro-cap with no EPS or consensus comparison disclosed